Showing 3801-3810 of 9083 results for "".
- Biologics Most Likely to Be Continued After MACE: Studyhttps://practicaldermatology.com/news/biologics-most-likely-to-be-continued-after-mace-study/2483287/Biologic therapies were linked with greater treatment persistence than non-biologic systemic agents or phototherapy among patients with psoriasis who experience major adverse cardiovascular events (MACE), according to findings from a retrospective study of Korean n
- Skin Microbiome and Aging: Connected for the Long Haul?https://practicaldermatology.com/news/skin-microbiome-and-aging-connected-for-the-long-haul/2483286/The skin microbiome is not just a passive reflection of age, but in fact may be a key player in how skin ages and its ability to resist decline. During her presentation on the intersection of microbiomes and skin aging at the 2025 Science of Skin Summit in Austin, TX, Julia Oh, PhD, a prof
- Long-Term Data Support Safety of Upadacitinib in Women With AD Using OCPshttps://practicaldermatology.com/news/long-term-data-support-safety-of-upadacitinib-in-women-with-ad-using-ocps/2483285/Upadacitinib maintains a favorable benefit–risk profile in women with moderate-to-severe atopic dermatitis (AD), regardless of oral contraceptive pill (OCP) or hormone replacement therapy (HRT) use, according to long-term safety data presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) C
- Analysis Links NHR With Increased Risk of PsOhttps://practicaldermatology.com/news/analysis-links-nhr-with-increased-risk-of-pso/2483261/The neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) is independently associated with an increased risk of psoriasis, raising the possibility of a novel biomarker for risk stratification, according to a large cross-sectional analysis of US adults published in Frontiers in Immuno
- Arcutis Seeks FDA Greenlight to Expand ZORYVE for Children Under 6https://practicaldermatology.com/news/arcutis-seeks-fda-greenlight-to-expand-zoryve-for-children-under-6/2483230/Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children aged 2 to 5, according to
- Study: Azelaic Acid Shows Positive Outcomes in Pregnant Acne Patientshttps://practicaldermatology.com/news/study-azelaic-acid-offers-superior-outcomes-in-pregnant-acne-patients/2483218/New retrospective data on topical therapies for acne vulgaris during pregnancy suggested azelaic acid demonstrated greater efficacy compared to erythromycin or clindamycin. The study, conducted between 2018 and 2022, analyzed
- Analysis: GLP-1 Receptor Agonists Linked with Reduced Surgical/Hospitalization Burden in HShttps://practicaldermatology.com/news/analysis-glp-1-receptor-agonists-reduced-surgical-and-hospitalization-burden-in-hs/2483172/New real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked with reduced surgical interventions and hospitalizations in patients with hidradenitis suppurativa (HS). Researchers using real
- Study: Tralokinumab Demonstrates Durable Response, High Retention in AD Patientshttps://practicaldermatology.com/news/tralokinumab-shows-strong-one-year-results-in-real-world-ad-study/2483171/The long-term use of tralokinumab in adults with moderate-to-severe atopic dermatitis (AD). Over a 52-week period, the IL-13 inhibitor demonstrated clinically meaningful and sustained improvements across multiple outcome measures, with a favorable safety profile and
- Bimekizumab Achieves Dual Clearance of Nail and Skin Psoriasishttps://practicaldermatology.com/news/bimekizumab-achieves-dual-clearance-of-nail-and-skin-psoriasis/2483170/In pooled analyses of phase III and IIIb trials, bimekizumab was associated with significantly higher rates of complete clearance of both skin and nail psoriasis compared to adalimumab, ustekinumab, and secukinumab in patients with moderate-to-severe plaque psorias
- Analysis: Global Prevalence of Hidradenitis Suppurativa Higher Than Previously Estimatedhttps://practicaldermatology.com/news/analysis-global-prevalence-of-hidradenitis-suppurativa-higher-than-previously-estimated/2483148/The estimate of the global prevalence of hidradenitis suppurativa (HS) sits at 0.99%, which notably higher than prior global figures, according to a new analysis. The research team compiled data from 25 population-based studies